In development [GID-TA10331] Expected publication date: 01 April 2020
Everything NICE has said on renal (kidney) cancer in an interactive flowchart
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal (kidney) cancer
In development [GID-TA10459] Expected publication date: 08 April 2020
Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy; keyhole surgery to remove a kidney)
This quality standard covers preventing, detecting and managing acute kidney injury in adults, young people and children. Acute kidney injury is sudden damage to the kidneys, which can sometimes result in kidney failure. The quality standard includes assessment by non-specialists and when to refer to specialist services. It describes high-quality care in priority areas for improvement.
Everything NICE has said on kidney (renal) conditions in an interactive flowchart
Evidence-based recommendations on percutaneous cryotherapy for renal (kidney) cancer
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment
This guideline covers assessing and managing urinary incontinence in children, young people and adults with neurological disease. It aims to improve care by recommending specific treatments based on what symptoms and neurological conditions people have.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults
Evidence-based recommendations on pemetrexed disodium (Alimta) for the first-line treatment of non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on percutaneous radiofrequency ablation for treating renal (kidney) cancer
Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy
Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma (RCC/kidney cancer) in adults
Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults
This guideline covers preventing, identifying and managing neutropenic sepsis in children, young people and adults receiving treatment for cancer in the community and in secondary and tertiary care. It aims to reduce the risk of infection in people with neutropenia (low number of white blood cells) who are receiving anticancer treatment and improve management of neutropenic sepsis.
Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after
Evidence-based recommendations on laparoscopic partial nephrectomy (keyhole surgery to remove kidney tumours)
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults
Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)
Evidence-based recommendations on topotecan (Hycamtin) for treating recurrent stage IVB (stage 4B) cervical cancer (cancer of the cervix)
Evidence-based recommendations on axitinib (Inlyta) for treating advanced renal cell carcinoma (RCC) (kidney cancer) when prior systemic treatment has failed
Everything NICE has said on urogenital conditions in an interactive flowchart
Evidence-based recommendations on pemetrexed (Alimta) for treating malignant pleural mesothelioma (cancer)
Evidence-based recommendations on irreversible electroporation (IRE) for treating liver metastases (secondary cancers)
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)
Evidence-based recommendations on laparoscopic cryotherapy (keyhole surgery to destroy cancer cells by freezing) for treating renal (kidney) cancer
This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.
Evidence-based recommendations on irreversible electroporation (IRE) for treating primary lung cancer and metastases in the lung
This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Everything NICE has said on the recognition, diagnosis and early management of sepsis in an interactive flowchart
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.
This guideline covers the recognition, diagnosis and early management of sepsis for all populations. The guideline committee identified that the key issues to be included were: recognition and early assessment, diagnostic and prognostic value of blood markers for sepsis, initial treatment, escalating care, identifying the source of infection, early monitoring, information and support for patients and carers, and training and education.
This guideline covers managing acute and chronic pancreatitis in children, young people and adults. It aims to improve quality of life by ensuring that people have the right treatment and follow-up, and get timely information and support after diagnosis.
This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Advice on the use of the NGAL Test for early diagnosis of acute kidney injury (AKI) to aid local decision-making
galantamine and memantine (review) 13-14 August 2006 TA142 Anaemia (cancer-treatment induced) - Erythropoetin (alpha and beta) and...
Evidence-based recommendations on minimally invasive (keyhole) video-assisted parathyroidectomy to remove abnormal parathyroid glands
Winners and finalists of our Shared Learning awards
breathlessness and COPD (MISSION ABC) Linking NICE acute kidney injury quality standards with Think Kidneys resources...
Everything NICE has said on assessing, diagnosing, treating and reducing the risk of venous thromboembolism in adults in an interactive flowchart
Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.